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Abstract Rotavirus gastroenteritis (RV GE) is a leading
cause of diarrhoea in young children. The purpose of this
epidemiological surveillance was to measure the disease
burden of RV GE among children <5 years of age in two
regions of Switzerland, Geneva and Lucerne. One hospital and
four paediatricians participated per region. The surveillance
lasted from December 2006 to June 2007. The population
denominator for calculation of the RV GE incidence rate was
the average of the overall study population <5 years of age
under surveillance during the surveillance period. At the study
sites, 513 children with GE were presented. Stool sample was
collected and examined in 341 cases, of which 130 were
RV positive (38.1%). Informed consent to participate in the
study was obtained for 113 RV positive subjects. The
overall RV GE incidence rate was 0.97% in Lucerne [lower
incidence interval (LCI), 0.71%; upper incidence interval
(UCI), 1.2%] compared with 0.65 and in Geneva (LCI,
0.50%; UCI, 0.81%). Disease severity assessments using
the Vescari score showed that the RV GE episodes were
more severe in Lucerne than in Geneva (14.05±3.05 vs
12.85±2.87), which was confirmed by a higher hospital-
isation rate in Lucerne at the study visit (82.9% vs 23.6%).
More children had fever in Geneva than in Lucerne (42.9%
vs 26.8%), and more children were hospitalised during the
follow-up period in Geneva than in Lucerne (14.5%
vs 2.5%). Genotyping of RV positive stool samples
revealed that both G1 and P8 were the most prevalent
types in both regions. There was a statistically significant
difference in the distribution frequency of G1 between the
two regions (p=0.039). Assessment of health economic data
confirmed the economic burden of RV GE episodes. In
conclusion, RV GE episodes are a health burden as well as
an economic burden also for the children in a developed
country such as Switzerland.
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Introduction
Rotavirus (RV) is the most common cause of severe,
dehydrating gastroenteritis (GE) in infants and young
children in developed and developing countries [5, 17].
By the age of 3–5 years, 95% of children worldwide have
been infected [20]. RV causes approximately 140 million
cases of diarrhoea annually accounting for 20% of
outpatient or clinic visits for diarrhoea, 26% of hospital-
isations for diarrhoea and a total of 452,000 deaths in
children under 5 years of age. However, in industrial
countries, mortality due to RV is low [21].
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RV is a double-stranded RNA virus with three protein
layers (capsids) surrounding the genome [6]. Variability in the
two outer layer proteins VP7 and VP4 results in different G,
respectively, P geno- and serotypes. Both VP7 and VP4
proteins induce neutralising antibodies and are therefore
important targets for vaccine development [10]. The preva-
lence of the four major RV strains (G1P [10], G2P [5], G3P
[10] and G4P [10]) can vary considerably from year to year
and from one geographic area to another [24]. Although RV
is detected year-round [1], the disease has a winter seasonal
pattern in developed countries with a temperate climate.
The primary burden of RV GE is on child health. However,
RV as a cause of severe vomiting and diarrhoea, leading to
dehydration and hospitalisation, also places significant eco-
nomic burden on health care systems and society [4, 12, 26].
This health and economic burden might be reduced by RV
vaccination. In the USA, it was found that vaccination
delayed RV activity during current season in onset by
2–4 months and diminished its magnitude by >50% when
compared with 15 previous seasons [25]. After the introduc-
tion of RV vaccination programmes, a reduction in the
number of hospitalisations and child deaths would be
expected in developing countries, while a reduction in the
number of clinic visits, hospitalisations and lost work days
would be expected in developed countries [13]. Recently, the
cost-effectiveness of RV vaccination has been assessed in
several countries. The outcomes of RV vaccination evalua-
tion in England and Wales showed that while immunisation
could reduce morbidity burden, the cost-effectiveness seems
not to be attractive enough [15, 16]. Similar findings were
obtained in the USA [28] and Australia [19]. So far, in
Switzerland one licensed RV vaccine exists, but RV
vaccination is listed as vaccine without recommendation in
the official Swiss vaccination plan 2009 [3].
The purpose of this pilot epidemiological study was to
estimate the disease burden ofRVGE among children <5 years
of age in two regions of Switzerland, Lucerne and Geneva,
using paediatrician- and hospital-based surveillance. The
primary objective was to estimate the RV GE incidence rate
in a defined area. The secondary objectives were to determine
(1) the age distribution of RV positive patients, (2) the disease
severity and (3) the prevalence of RV genotypes. Furthermore,
(4) the socioeconomic impact of the RV GE episode was
analysed.
Materials and methods
Study design
We conducted an observational, prospective, paediatrician-
and hospital-based, multi-centre, epidemiological study in
primary but no nosocomial RV GE positive children <5 years
of age in the cantons of Geneva and Lucerne between
December 2006 and June 2007. The study was approved by
the Ethic Committee of Geneva and Lucerne, respectively.
There were one hospital and four paediatric offices
participating per region. Sites were considered an appropri-
ate selection of possible study sites per region.
All children <5 years of age presenting at the selected
study sites with acute GE, defined as the production of
three or more watery or looser than normal stool or forceful
vomiting within a 24-h period, were proposed to participate
in the study. When oral consent of parents/guardians was
given, a stool sample was collected from the children with
acute GE and tested for RV using Vikia rapid test kit
(Vikia® Rota-Adeno, bioMérieux, S.A.).
Only children with positive RV rapid test and whose
parents gave written informed consent, who were attainable
by telephone and communicate in a local language, were
included in the study. Children suffering from an underlying
chronic gastrointestinal tract disease and children who had
been hospitalised within the last 14 days prior to the visit were
excluded from the study. During the study visit, the disease
severity was assessed using the 20-point-scale method by
Vesikari [23].1 Demographics, medical history, risk factors
and additional costs were collected by means of a case report
form. Based on the outcome of the study visit, patients were
classified into several subgroups termed “sent home”, “sent
to a specialist”, “sent to the emergency room”, “hospitalised”
and “scheduled for a further visit”. All patients seen at the
two hospital sites were emergency contacts and considered
as having had at least a “hospital visit”.
A follow-up phone call to the parents/guardians of the
enrolled child 14 days after the study visit completed the
study for the enrolled patient. During the follow-up
telephone call, the health status of the child was assessed,
and data on further economic costs were collected.
Variables such as full recovery, necessity to contact a
medical facility after the study visit and hospitalisation due
to the same episode of RV GE were also recorded.
Stool samples
Genotyping was performed by RT-PCR on RV-positive
stool specimens. Briefly, nucleic acids were extracted
using an automated system based on magnetic beads
(easyMAG, bioMérieux, Boxtel, The Netherlands) and
then reverse transcribed using random hexamers. G-types
were determined by amplification of the VP7 gene with
1 The score assesses the duration of diarrhoea, the maximal number
of episodes of diarrhoea per day, duration of vomiting, maximal
number of episodes of vomiting per day, maximal rectal temper-
ature, the degree of dehydration and treatment (oral rehydration or
hospitalisation).
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one consensus (End9) and six type-specific primers as
described previously [14]. In cases of uncertain assign-
ment, the amplicon obtained with consensus primers
Beg9/End9 was sequenced. P-typing included amplifica-
tion of the VP4 gene with two consensus primers (con2/
con3 [10]) followed by sequence analysis and comparison
to sequences deposited in GeneBank.
Demographic data
Children were grouped in age groups of 1 year and by
Swiss or non-Swiss nationality. Non-Swiss children were
defined as children living in the canton of Geneva or
Lucerne but having no Swiss passport.
Estimation of medical and societal costs
Data on medical costs related to the episodes of RV GE
were assessed by collecting the anonymised invoices
(according to TarMed system), which included costs for
laboratory test and drugs dispensed in the centre. Extra
expenses such as for medication, nutritional products,
transportation and others covered by parents were assessed
at the study visit and at the follow-up call. Societal costs
such as loss of working days, necessity to organise day
nurse and missed nursery or playschool hours were also
assessed at the follow-up call.
Sample size
The population under surveillance was expected to be
between 5,000 and 10,000 children <5 years served by the
sites selected for the study. It was calculated that this would
allow detection of an adequate number of RV GE cases
among these children (e.g., assuming an expected RV GE
incidence rate for cases leading to physician consultation of
two cases per 100 children-years, one would expect to see
between 100 and 200 RV GE cases for a population under
surveillance of 5,000–10,000 children <5 years of age)
Statistical analysis
The data of the intent to treat (ITT) population are
presented. The ITT population comprised all study subjects
including children where follow-up period exceeded
20 days
The incidence of RV GE leading to a physician or
hospital (study site) visit among children <5 years of age
overall and by 1 year age groups was calculated with 95%
CI. The population denominator for the incidence was the
average of the overall study population <5 years of age per
region under surveillance during the surveillance period.
This analysis was performed for all RV GE episodes with
positive results on a rapid stool test and confirmed at the
central laboratory. The used statistical test procedures were
the chi-square test to compare several incidence proportions
and the z test for comparing proportions.
Quantitative parameters were analysed using t test for
comparing the means of two groups and ANOVA for
comparing the means of several groups. p values <0.05
were considered statistically significant.
Results
Study population
The per protocol analysis population consisted of 87
patients, and the ITT population consisted of 113 patients.
Only results of ITT population are presented and discussed
below.
Overall, 513 children suffering from acute GE were seen
at the sites. After obtaining oral consent from parents, stool
samples of 341 children were collected of which 130 were
tested positive for RV. Ensuing 113 patients of these RV
positive patients were enrolled in the study. Further details
are given in Table 1.
Demographic characteristics
The age distribution of children enrolled in the study was
analysed for the regions Geneva and Lucerne in subpopu-
lation of 1-year age groups. The majority of children
enrolled in the study were between 0 and 1 year (overall
41.6%, n=47) and 1–2 years (overall 44.2%, n=50). Eight
per cent (n=9) of all children were between 2 and 3 years,
5.3% (n=6) between 3 and 4 years and 0.9% (n=1)
between 4 and 5 years old. No statistically significant
differences in the distribution of age groups were observed
between the two regions.
In Geneva, 50% of the children enrolled were of Swiss
nationality, and 50% were of non-Swiss nationality. In
Table 1 Overview of the screened population at the centres in
Geneva and Lucerne
Number of children Geneva Lucerne Overall
With acute GE 127 386 513
Where an oral consent was given 127 231 358
Where a stool sample was collected 114 227 341
Positive for RV 73 57 130
Where written consent was given 72 43 115
Enrolled in the study 72 41 113
In some children, it was not possible to obtain a stool sample. In two
patients, the consent was withdrawn
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Lucerne, 75.6% of children enrolled were of Swiss
nationality, and 24.4% were of non-Swiss nationality. There
was a significant difference in the distribution (p=0.008).
Incidence rate of RV GE
The incidence rates of GE are shown in Fig. 1a. The GE
incidence rate in Lucerne [6.6%; lower incidence interval
(LCI), 5.9%; upper incidence interval (UCI), 7.2%] was
higher than in Geneva (1.1%; LCI, 0.94%; UCI, 1.3%) based
on the study population of children under 5 years. The
overall incidence rate was 3.0%±0.26%. In both cantons,
children under 2 years were markedly more susceptible for
GE compared to the older children. The incidence rates were
highest in these age classes (3.5–3.9%).
The incidence rates of RV GE are shown in Fig. 1b. The
RV GE incidence rate was higher in Lucerne (0.97%; LCI,
0.71%; UCI, 1.2%) than in Geneva (0.65%; LCI, 0.50%;
UCI, 0.81%). The overall incidence rate was.0.76% (LCI,
0.63%; UCI, 0.90%). The incidence rates for children under
2 years were higher compared to the children 2–5 years old.
RV GE accounted for 36.3% of GE cases among the study
population. This percentage was markedly higher in Geneva
than in Lucerne (57.5% vs 24.7%). See also Table 1.
To evaluate whether the children of certain age groups were
more prone to RV GE, the age distribution in the study sites
population (n=17,042, e.g., all children seen at all study sites
regardless of indication) and the population of children
enrolled in the study (n=113, “RV GE sample”) were
compared. There were statistically significant differences in
the age distribution between these populations (p<0.001).
The proportion of children younger than 2 years was higher
in the “RV GE sample” (85.8%) compared to the all study
sites population (57.0%).
To evaluate whether the incidence rates (IR) varied among
children that were initially seen at a hospital (with and without
hospitalisation during the study period) or at a paediatrician
practice, the incidence rates were calculated separately for
these subpopulations. The highest RV GE IR was found in
children seen at hospital (overall, 0.61%; LCI, 0.49%; UCI,
0.73%), then in children seen at the hospital and hospitalised
at visit or during the follow-up period (overall, 0.38%; LCI,
0.29%; UCI, 0.48%). The RV GE IR was lowest in children
seen at the paediatrician only (overall, 0.15%; LCI, 0.09%;
UCI, 0.21%). For the subpopulations “hospital visit” and
“hospital visit and hospitalised”, the incidence rates were
higher in Lucerne compared to Geneva.
Severity of RV GE
The relative abundance of RV GE clinical symptoms such
as fever, vomiting and diarrhoea was checked. No statisti-
cally significant differences were found for the distribution
of the vomiting and diarrhoea between the regions Geneva
and Lucerne. However, there was a higher proportion of the
children having fever at the study visit in Geneva in
comparison with Lucerne (42.9% vs 26.8%; p=0.091).
To estimate the disease severity, the Vesikari score was
recorded and the data analysed. A higher mean Vesikari
score was reached in the region Lucerne than in Geneva
(14.05±3.05 vs 12.85±2.87; p=0.039).
Outcome
The analysis of the data revealed a significant difference
between the two regions in outcome variables assessed at
the study visit (p<0.001). A higher proportion of children
were hospitalised in Lucerne at the study visit when
compared with Geneva (82.9% vs 23.6%; p<0.001);
accordingly, 60.4% of children seen in Geneva were sent
home vs 11.8% of children seen in Lucerne (p<0.001).
More children were scheduled for a follow-up visit in
Geneva than in Lucerne (11.3% vs 2.9%; p<0.001).
However, more children had to be hospitalised during the
follow-up period in Geneva than in Lucerne (14.5% vs
2.5%; p=0.045). The median duration of clinical symptoms
was 8.3 days; the median duration of hospitalisation was
3 days. No statistical differences were found between the
regions Geneva and Lucerne regarding the full recovery of
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Fig. 1 a Incidence rates (IR) by site region and age for acute
gastroenteritis (GE) calculated with 95% CI and based on the overall
study population by age group. b Incidence rates (IR) by site region
and age for acute rotavirus gastroenteritis (RV GE) calculated with
95% CI and based on sthe overall study population by age group
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the patients and regarding the necessity to contact a medical
facility or a paediatrician.
Distribution of RV genotypes
Genotyping was performed on 113 RV positive stool samples
using VP7 primers and VP4 primers. The distribution of the
G-types among the regions was statistically significantly
different (p=0.039), with the G1-type being the most
prevalent one in both regions (74.1% in Geneva and 51.5%
in Lucerne; Table 2). Among the P types, P[8] was
dominating in both regions (89.6% in Geneva and 57.1%
in Lucerne, Table 2). The distribution of P types did not
differ significantly between the two regions.
Health economics data: cost identification analysis
The total sum of 109,800 Swiss francs (CHF)/72,638 EUR
(37,254 CHF/24,645 EUR in Geneva and 72,546 CHF/
47,993 EUR in Lucerne) was invoiced by hospitals and
paediatricians for acute RV GE episodes (currency rate
CHF/EUR=1/1.5116). The mean direct costs were 998±
1,034 CHF/660±684 EUR overall, 540±734 CHF/357±486
EUR for Geneva and 1,769±1,001 CHF/1,170±662 EUR for
Lucerne.Mean costs were calculated for the following groups:
(1) patients seen at the hospitals (direct costs of 1,242±1,046
CHF/1,170±662 EUR overall, 672±814 CHF/1,170±662
EUR for Geneva and 2,114 ±705/822±466 EUR for
Lucerne); (2) patients seen at the hospital and hospitalised at
the study visit or during the study follow-up (direct costs of
1,927±861 CHF/1,275±570 EUR overall, 1,501±1,045
CHF/993±691 EUR for Geneva and 2,114±705/1,399±466
EUR for Lucerne); and (3) patients seen at a paediatrician and
no hospitalisation (direct costs of 126±67 CHF/83±67 EUR
overall, 135±74 CHF/89±49 EUR for Geneva and 100±37/
66±24 EUR for Lucerne).
The indirect medical costs paid by parents/guardians,
such as extra expenses for medication, nutritional products,
and transportation and others, were relatively small.
At follow up, it was assessed that 2.9±2.36 working
days were lost overall, 3.30±2.84 in Geneva and 2.35±1.31
in Lucerne. Overall, 21.58±15.36 day nurse hours were
needed at the overall costs of 160.60±325.70 CHF/106±
215 EUR. Overall, 47.7±74.4 kindergarten hours were
missed, 52.2±80.0 in Geneva and 25.2±32.5 in Lucerne.
Discussion
This study provides data on the burden of RV GE among
children <5 years of age in two regions of Switzerland,
Geneva and Lucerne, a more urban and a more rural region,
respectively. The incidence rate of RV GE episode in a
defined area was determined. Furthermore, demographic
parameters, data on the severity of the RV GE episode, the
prevalence of RV genotypes and socioeconomic data were
assessed. Since in countries with moderate climate, the
majority of RV GE cases occur in winter [1], the period
from December to June was chosen to perform the study.
During the study period, the incidence rate of GE was
higher in Lucerne than in Geneva, possibly reflecting the
difference in obtaining the consent between the two
G-typea P-typeb Percentage (%)
4 8 other total 4 8 other total
Geneva 1 0 43 0 43 0.0 89.6 0.0 74.1
2 3 2 0 5 60.0 4.2 0.0 8.6
3 0 1 0 1 0.0 2.1 0.0 1.7
4 1 1 0 2 20.0 2.1 0.0 3.4
9 0 1 0 1 0.0 2.1 0.0 1.7
Other 1 0 5 6 20.0 0.0 0.0 10.3
Total 5 48 5 58 100.0 100.0 0.0 100.0
Unknown 14
Lucerne 1 0 16 1 17 0.0 57.1 25.0 51.5
2 1 2 0 3 100.0 7.1 0.0 9.1
3 0 3 0 3 0.0 10.7 0.0 9.1
4 0 3 0 3 0.0 10.7 0.0 9.1
9 0 4 0 4 0.0 14.3 0.0 12.1
Other 0 0 3 3 0.0 0.0 75.0 9.1
Total 1 28 4 33 100.0 100.0 100.0 100.0
Unknown 8
Table 2 Cross-table PCR geno-
typing for rotavirus strains by
site region
a Statistically significant differ-
ence in distribution of G-types
between the two regions
(p=0.039)
b No statistically significant dif-
ference in distribution of P-types
between the two regions
(p>0.05)
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regions. The incidence rate of RV GE was different in
children seen at hospital or at the paediatrician. More cases
were seen at the two hospital sites than at the paediatricians.
Whereas in Geneva, the consent to perform RV GE rapid
test was obtained in all GE cases; in Lucerne, the consent
was given only by 59.84% parents of the GE positive
children. Differences in consenting might reflect differences
in mentality between the two regions. On the other side, it
can be assumed that the incidence rate of RV GE is similar
in the “children without consent” as in the “children with
consent” given. In comparison with other studies, the RV
GE incidence rate was quite low in our study. However, the
surveillance period was only one season. Laubereau et al.
[18] described an incidence rate of RV GE in the season
1997/1998 of 1.6%. In Germany, based on federal statistics
from years 2001–2004, the incidence rate of RV GE in
children below 4 years was 1.2% [8], and the incidence rate
of RV GE was higher in children younger than 2 years than
in the older age groups, as it was found in several studies
[7, 18, 22, 29]. Similarly, the percentage of <2 years
children was also substantially higher in our study
population than in the overall site population, suggesting
that children <2 years are more prone to RV GE compared
to older children. A recent Swiss study investigating RV
infections in children <5 years of age indicated the peak
incidence of RV GE for children aged 13–24 months [2].
The higher incidence rate for RV GE (1.5%) in this study
compared with the current data was probably due to the
longer observation period (5 years).
In comparison with other studies, the RV GE
incidence rate was low in our study, which might be
attributed to several reasons. The 6-month period in our
study may not be representative for the seasonal
distribution and temporal variability of RVGE incidence
during a whole year. In addition, the fact that cases were
not selected from all hospitals in the canton Lucerne may
constitute reasons for the lower incidence rates in this
study compared to other European investigations. Selec-
tion bias, especially related to those who did not provide
informed consent, may also have contributed to the low
estimates compared to other studies.
To estimate the disease severity, the Vesikari score was
recorded. Higher mean Vesikari score was reached in
Lucerne than in Geneva. Nevertheless, there were no
differences in full recovery of the patients between both
sites. Overall hospitalisation varied from 37.7% in Geneva
and 82.4% in Lucerne. This striking difference in hospital-
isation rate and in the mean Vesikari scores (which includes
the need for hospitalisation) discussed above can be
explained by the possibility to keep patients in the
emergency unit for less than 24 h on an outpatient basis
in Geneva, whereas children needing supportive care in
Lucerne had to be hospitalised, even for a short period of
time. Differences in outcome and hospitalisation rates
between cantons most probably rather reflect differences
in mentality and admission policy rather than true
differences of disease severity, as the criteria for
admission were not standardised. The incidence of RV
hospitalisation has been investigated in several studies.
In the REVEAL study performed in the several
countries, the estimated percentage of children with RV
GE admitted to a hospital was 10.4–36.0%. These
hospitalisation rates are slightly lower than the overall
hospitalisation rate in our study at the study visit
(45.9%). Furthermore, the relative risk of hospitalisation
was significantly higher for children with RV positive
GE than for those with RV negative GE [11]. Another
study performed in Italy in children <5 years and
analysing data from the period of January 2001 to
December 2005 showed that 36% of GE-related hospital-
isations were attributed to RV GE [9].
Since the prevalence of the distinct RV strains can vary
considerably from year to year and from one geographic area
to another [24], genotyping was performed to compare the
distribution of different RV strains in the regions Geneva and
Lucerne. Indeed, regional differences in the distribution of
distinct G-type strains were observed. However, the G1-type
was the most prevalent one in both regions. Laubereau et al.
[18] identified G4 and G1 as the most prominent strains
during the study period 1998/1999. Differences in the RV
genotypes distribution were also observed in the REVEAL
study performed in the RV GE season 2004–2005. G1 was
identified in Spain, Sweden and UK, G9 in Italy, France and
Belgium and G4 in Germany. Only the G4 and G9
genotypes were identified in all study areas [27].
In addition to the health burden, it is obvious that RV
GE places also economic burden on society. The
socioeconomic parameters presented in our study allow
only rough estimations since collected data were limited.
More appropriate socioeconomic data from seven Euro-
pean countries have been published recently [12]. A well
sampled, truly multi-centre, nationwide and multi-season
study with clearly defined outcome variables and a
standardised methodology would be highly valuable and
add to the current bulk of evidence. Appropriate collection
of health economic data including modelling shall also be
done for Switzerland.
Conclusions
The incidence rates of RV GE were similar in both study
regions with the peak incidence rate in the group of children
under 2 years. Overall, the incidence rate was very low
(0.32%) compared with other studies. In both regions, G1 was
the most prevalent RV genotype. However, there were
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regional differences in relative distribution of distinct geno-
types. RV GE was also associated with considerable socio-
economic costs. Suitable health economic model calculations
will help to estimate real socioeconomic burden of RV GE
episode in Switzerland.
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